ACHN : Analysis & Opinions

  1. 3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog

    December 30, 2014
    Gilead (GILD) has been under pressure due to the pricing of its hepatitis C virus (HCV) treatments.
  2. Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen ...

    December 24, 2014
    Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) ...
  3. Achillion Gains on Positive Results from its HCV Candidates - ...

    December 23, 2014
    Achillion Pharmaceuticals (ACHN) gained more than 9% after announcing encouraging results from its HCV candidates.
  4. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  5. Like Volatility? Trade These Four Stocks

    September 3, 2014
    These four stocks have seen wide moves over the last 30 days, offering big short-term potential for those willing to take ...
  6. Buyout Cycle Boosts Biotech ETFs

    June 16, 2014
    The 230% single day gain that IDIX experienced as a result of the buyout had a huge impact on the SPDR Biotechnology ETF ...
  7. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  8. Bristol-Myers Pays A Premium For Its Partner

    September 10, 2010
    Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
  9. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
Trading Center